MS Nurse Learning Program

UNDERSTANDING THE IMMUNE SYSTEM AND PROPOSED MECHANISM OF ACTION OF MAVENCLAD® (CLADRIBINE) TABLETS





IMPORTANT SAFETY INFORMATION

INDICATION

MAVENCLAD® (cladribine) tablets is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsingremitting disease and active secondary progressive disease, in adults. Because of its safety profile, use of MAVENCLAD is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS.

Limitations of Use: MAVENCLAD is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile.

IMPORTANT SAFETY INFORMATION

WARNING: MALIGNANCIES and RISK OF TERATOGENICITY

- Treatment with MAVENCLAD may increase the risk of malignancy. MAVENCLAD is contraindicated in patients with current malignancy. In patients with prior malignancy or with increased risk of malignancy, evaluate the benefits and risks of the use of MAVENCLAD on an individual patient basis. Follow standard cancer screening guidelines in patients treated with MAVENCLAD
- MAVENCLAD is contraindicated for use in pregnant women and in women and men of reproductive potential who do not plan to use effective contraception because of the potential for fetal harm. Malformations and embryolethality occurred in animals. Exclude pregnancy before the start of treatment with MAVENCLAD in females of reproductive potential. Advise females and males of reproductive potential to use effective contraception during MAVENCLAD dosing and for 6 months after the last dose in each treatment course. Stop MAVENCLAD if the patient becomes pregnant

CONTRAINDICATIONS

- Patients with current malignancy.
- Pregnant women, and women and men of reproductive potential who do not plan to use effective contraception during and for 6 months after the last dose in each treatment course. May cause fetal harm.
- Patients with human immunodeficiency virus (HIV).
- Patients with active chronic infections (e.g., hepatitis or tuberculosis).
- Patients with a history of hypersensitivity to cladribine.
- Women intending to breastfeed while taking MAVENCLAD tablets and for 10 days after the last dose.

WARNINGS AND PRECAUTIONS

- Malignancies: Treatment with MAVENCLAD may increase the risk of malignancy. After the completion of 2 treatment courses, do not administer additional MAVENCLAD treatment during the next 2 years. In clinical studies, patients who received additional MAVENCLAD treatment within 2 years after the first 2 treatment courses had an increased incidence of malignancy. The risk of malignancy with reinitiating MAVENCLAD more than 2 years after the completion of 2 treatment courses has not been studied. Follow standard cancer screening guidelines in patients treated with MAVENCLAD.
- Risk of Teratogenicity: MAVENCLAD may cause fetal harm when administered to pregnant women. In females of reproductive potential, exclude pregnancy before initiation of each treatment course of MAVENCLAD and prevent by the use of effective contraception during MAVENCLAD dosing and for at least 6 months after the last dose of each treatment course. Women who become pregnant during treatment with MAVENCLAD should discontinue treatment.

- lymphocyte counts before and during treatment, periodically thereafter, and when clinically indicated.
- cladribine in patients with MS.
- and during treatment, periodically thereafter, and when clinically indicated.
- treatment. Discontinue if clinically significant injury is suspected.
- MAVENCLAD therapy. Do not use MAVENCLAD in patients with a history of hypersensitivity to cladribine.
- cladribine used for treatment indications other than multiple sclerosis.

Adverse Reactions: The most common adverse reactions with an incidence of >20% for MAVENCLAD are upper respiratory tract infection, headache, and lymphopenia.

Drug Interactions/Concomitant Medication: Concomitant use of MAVENCLAD with immunosuppressive or myelosuppressive drugs and some immunomodulatory drugs (e.g., interferon beta) is not recommended and may increase the risk of adverse reactions. Acute short-term therapy with corticosteroids can be administered.

Avoid concomitant use of certain antiviral and antiretroviral drugs. Avoid concomitant use of BCRP or ENT/CNT inhibitors as they may alter bioavailability of MAVENCLAD.

Use in Specific Populations: Studies have not been performed in pediatric or elderly patients, pregnant or breastfeeding women. Use in patients with moderate to severe renal or hepatic impairment is not recommended.

Please see the accompanying full Prescribing Information, including **boxed WARNING** for additional information.

 Lymphopenia: MAVENCLAD causes a dose-dependent reduction in lymphocyte count. In clinical studies, 87% of MAVENCLADtreated patients experienced lymphopenia. The lowest absolute lymphocyte counts occurred approximately 2 to 3 months after the start of each treatment course and were lower with each additional treatment course. Concomitant use of MAVENCLAD with hematotoxic drugs may increase the risk of adverse reactions because of the additive hematological effects. Monitor

Infections: MAVENCLAD can reduce the body's immune defense and may increase the likelihood of infections. Infections occurred in 49% of MAVENCLAD-treated patients compared to 44% of patients treated with placebo in clinical studies. The most frequent serious infections included herpes zoster and pyelonephritis. Single fatal cases of tuberculosis and fulminant hepatitis B were reported in the clinical program. Administer live-attenuated or live vaccines at least 4 to 6 weeks prior to starting MAVENCLAD. Screen patients for latent infections; consider delaying treatment until infection is fully controlled. Vaccinate patients antibodynegative to varicella zoster virus prior to treatment. Administer anti-herpes prophylaxis in patients with lymphocyte counts less than 200 cells per microliter. Monitor for infections. In patients treated with parenteral cladribine for oncologic indications, cases of progressive multifocal leukoencephalopathy (PML) have been reported. No case of PML has been reported in clinical studies of

 Hematologic Toxicity: In addition to lymphopenia, decreases in other blood cells and hematological parameters have been reported with MAVENCLAD in clinical studies. In general, mild to moderate decreases in neutrophil counts, hemoglobin levels, and platelet counts were observed. Severe decreases in neutrophil counts were observed in 3.6% of MAVENCLAD-treated patients, compared to 2.8% of placebo patients. Obtain complete blood count (CBC) with differential including lymphocyte count before

• Risk of Graft-versus-Host Disease With Blood Transfusions: Transfusion-associated graft-versus-host disease has been observed rarely after transfusion of nonirradiated blood in patients treated with cladribine for non-MS treatment indications.

• Liver Injury: In clinical studies, 0.3% of MAVENCLAD-treated patients had liver injury (serious or causing treatment discontinuation) compared to 0 placebo patients. Obtain serum aminotransferase, alkaline phosphatase, and total bilirubin levels prior to

• Hypersensitivity: In clinical studies, 11% of MAVENCLAD-treated patients had hypersensitivity reactions, compared to 7% of placebo patients. Hypersensitivity reactions that were serious and/or led to discontinuation of MAVENCLAD, occurred in 0.5% of MAVENCLAD-treated patients, compared to 0.1% of placebo patients. If a hypersensitivity reaction is suspected, discontinue

• Cardiac Failure: In clinical studies, one MAVENCLAD-treated patient experienced life-threatening acute cardiac failure with myocarditis, which improved after approximately one week. Cases of cardiac failure have also been reported with parenteral **01. INTRODUCTION**

02. MS IMMUNOLOGY

03. MAVENCLAD & THE IMMUNE SYSTEM

04. SUMMARY

05. CHECK YOUR KNOWLEDGE

06. ADDITIONAL RESOURCES

07. REFERENCES





INTRODUCTION








UNDERSTANDING THE IMMUNE SYSTEM AND THE PROPOSED MECHANISM OF ACTION OF MAVENCLAD® (CLADRIBINE) TABLETS

THE ROLE OF THE IMMUNE SYSTEM IN MS



HOW MAVENCLAD IS THOUGHT TO TARGET AND AFFECT THE IMMUNE SYSTEM

THIS SLIDE DECK AIMS TO HELP YOU:



Although MS is often described as a neurological condition, the immune system is critical to the pathology of the disease and, therefore, to disease management and treatment.^{1,2}



Be comfortable explaining the immune system to patients and answering patient questions in a level of detail appropriate for each patient



THE ROLE OF THE IMMUNE SYSTEM IN MS



BEFORE COMPLETING THIS LEARNING SESSION, PLEASE TAKE A FEW MOMENTS TO CONSIDER THE FOLLOWING QUESTIONS

You may want to note your answers and then revisit the questions after completing the learning.



To what extent do you feel you can apply your understanding of the immunology of MS to your practice in general, and in regard to educating patients with RMS?

What are your main areas of uncertainty?


A patient with RMS asks you how MAVENCLAD works. What would you say?

What are your main areas of uncertainty?



An RMS patient considering MAVENCLAD wants to know how the treatment has affected the immune systems of RMS patients.

What would you say to this patient? What are your main areas of uncertainty?





Although there is currently no cure, **there are multiple treatments approved for relapsing forms of MS**⁷

CIS

Clinically isolated syndrome⁸

RRMS

Relapsing-remitting multiple sclerosis⁸

PPMS

Primary progressive multiple sclerosis⁸


SPMS

Active secondary progressive multiple sclerosis⁸

MAVENCLAD is not recommended for use in people with CIS and is not approved in people with PPMS.

MAVENCLAD is approved to treat relapsing forms of MS to include relapsing-remitting and active secondary progressive. Because of its safety profile, MAVENCLAD is generally used in people who have tried another MS medicine that they could not tolerate or that has not worked well enough.³

LET'S TAKE A LOOK AT THE 2 TYPES OF MS THAT MAVENCLAD IS INDICATED FOR^{6,9,10}



Relapsing-remitting multiple sclerosis (RRMS) is the most common type of MS. Approximately 85% of people with MS are initially diagnosed with RRMS.^{6,8,10}

- It is characterized by clearly defined attacks of new or worsening MRI activity. These attacks-also called relapses or exacerbations-are followed by periods of partial or complete recovery (remissions). During remissions, all symptoms may disappear, or some symptoms may continue and become permanent
- New lesions on MRI may develop as part of a relapse. New MRI lesions indicating MS activity may also occur without symptoms of which the person is aware

Active secondary progressive multiple sclerosis (SPMS)


follows an initial relapsing-remitting course.¹¹

- Many people who are diagnosed with RRMS will eventually transition to an active secondary progressive course in which neurologic function (accumulation of disability) gets worse over time
- SPMS can be characterized at different points in time as either active or not active, as well as with progression or without progression
- MAVENCLAD is only for patients with active SPMS who continue to have relapses³



THE IMMUNE SYSTEM IS A COMPLEX NETWORK OF CELLS THAT WORK TOGETHER TO DEFEND THE BODY FROM INFECTION

These cells fall into 2 main groups: innate and adaptive






ADAPTIVE

T and B cells (also known as lymphocytes) listen to the innate cells and respond over days or weeks to eliminate the specific virus or infection.¹

memory so that the body is prepared the next time the harmful agent threatens the body.

YOUR IMMUNE SYSTEM IS A COMPLEX NETWORK OF CELLS THAT WORK TOGETHER TO DEFEND THE BODY FROM INFECTION

The immune system and MS






ADAPTIVE

In MS, T and B cells do not communicate properly and become overactive, leading them to mistakenly attack the nerves in the central nervous system. This causes damage and inflammation, which show up as lesions and MS-related symptoms.²


UNDERSTANDING THE ROLES OF IMMUNE CELLS IS IMPORTANT TO RECOGNIZING THE PATHOLOGY OF MS¹²

Innate immune cells: First line of defense, serve as immune surveillance



UNDERSTANDING THE ROLES OF IMMUNE CELLS IS IMPORTANT TO RECOGNIZING THE PATHOLOGY OF MS

Adaptive immune cells: Second line of defense, key drivers of neuroinflammation in MS









UNDERSTANDING HOW MAVENCLAD TARGETS AND AFFECTS THE IMMUNE SYSTEM

IN RMS, THERE ARE MULTIPLE TREATMENT APPROACHES TO CONSIDER THAT HAVE VARYING EFFECTS ON THE IMMUNE SYSTEM






IN RMS, THERE ARE MULTIPLE TREATMENT APPROACHES TO CONSIDER THAT HAVE VARYING EFFECTS ON THE IMMUNE SYSTEM



IN RMS, THERE ARE MULTIPLE TREATMENT APPROACHES TO CONSIDER THAT HAVE VARYING EFFECTS ON THE IMMUNE SYSTEM



MAVENCLAD IS THOUGHT TO WORK THROUGH IMMUNODEPLETION, FOLLOWED BY REPOPULATION



MAVENCLAD is associated with a reduction and subsequent


Lymphocytes generally recovered over several months or more and they may not go back to pre-treatment levels. Refer to slide 20 for the effect of MAVENCLAD on total lymphocytes.

Vaccination can be considered until 4-6 weeks prior to starting each MAVENCLAD course only if white blood cell counts are within normal limits. See more vaccine information on slide 30.

In an addition to lymphopenia, decreases in other blood cells and hematological parameters (neutrophils, hemoglobin, and platelets) have been reported with MAVENCLAD in clinical studies.

MAVENCLAD IS THOUGHT TO PREFERENTIALLY TARGET B AND T LYMPHOCYTES^{4,18,19}

MAVENCLAD is a prodrug that is preferentially activated in B and T lymphocytes^{4,18,19}



MAVENCLAD is a prodrug that is activated by specific kinases and deactivated by specific phosphatase.³


MAVENCLAD becomes active in the cells upon phosphorylation to its 2-chlorodeoxyadenosine triphosphate (Cd-ATP) metabolite.

Activated MAVENCLAD accumulates in B and T lymphocytes because they have a higher kinase-to-phosphatase ratio than other cells.¹⁸

The reduction of B and T lymphocytes by MAVENCLAD is believed to disrupt the immune cascade central to MS.¹⁸



EFFECTS OF MAVENCLAD ON TOTAL LYMPHOCYTES




For vaccination considerations and their relation to the lymphocytes as part of the white blood cell count, please see slide 30.

*Grade 1, <LLN-800/µL; 2, <800-500/µL; 3, <500-200/µL; 4, <200/µL.²⁰ *Visits with sample size ≥30 are displayed.⁴

[‡]Data were derived from a post hoc analysis of the 2 courses in patients receiving MAVENCLAD in CLARITY.⁴ [§]Percentages were calculated as a proportion of all patients with laboratory values at each time point. A total of 1.7% of patients (3/176) experienced >1 episode of Grade 4 lymphopenia at any time point during the entire trial period.⁴ ALC: absolute lymphocyte count; CLARITY: CLAdRIbine Tablets treating multiple sclerosis orallY; LLN: lower limit of normal.

Post hoc analysis, percentage of patients who had median ALC at Grade 1 lymphopenia or within normal limits^{4*†‡§}




Week 12 of Year 2

- Normal to Grade 1: **64.5%**
- Grade 2: 28.9%
- Grade 3: 6.7%


3

• Grade 4: 0.0%



TREATMENT WITH MAVENCLAD HAD THE FOLLOWING RESULTS ON SELECT ADAPTIVE AND INNATE IMMUNE CELLS

MAVENCLAD and the immune system




ADAPTIVE

MAVENCLAD is believed to work by targeting and reducing the number of T and B cells in the body so that there are fewer of them to attack the nerves.³ For most patients, the active ingredient in MAVENCLAD does not remain in the body beyond 1 week.^{3,18,24} The numbers of T and B cells reach their lowest level about 2–3 months after the start of each treatment course and are lower with each additional treatment course.³

TREATMENT WITH MAVENCLAD HAD THE FOLLOWING RESULTS ON SELECT ADAPTIVE AND INNATE IMMUNE CELLS

MAVENCLAD over time






ADAPTIVE

Although a majority of patients in clinical trials experienced mild to moderate lymphopenia (low Tand B-cell counts), most had their cell counts return to normal range. It may take several months or more for the recovery of the T and B cells, and they may not go back to pretreatment levels.^{3,4}


MAVENCLAD AND SELECT NATURAL KILLER (NK) CELLS

Post hoc analysis: median levels of NK cells remained




*204 patients from a post hoc analysis of CLARITY ([n=98] for placebo, [n=101] MAVENCLAD) had lymphocytes and additional blood cells analyzed. [†]Decreases in blood cells, other than lymphocytes, and hematological parameters have been reported with MAVENCLAD in clinical studies.³ [†]In general, mild to moderate decreases in neutrophil counts, hemoglobin levels, and platelet counts were observed. Severe decreases in neutrophil counts were observed in 3.6% of patients treated with MAVENCLAD, compared with 2.8% of placebo patients.³ BL: baseline; CLARITY: CLAdRIbine Tablets treating multiple sclerosis orallY; LLN: lower limit of normal.

MAVENCLAD AND SELECT NEUTROPHILS



*Post hoc analysis of patients taking MAVENCLAD (n=103) and placebo (n=101) from CLARITY had lymphocytes and additional blood cells analyzed. CLARITY: CLAdRIbine Tablets treating multiple sclerosis orally; LLN: lower limit of normal.^{19,22}


MAVENCLAD AND SELECT MONOCYTES



*Post hoc analysis of patients taking MAVENCLAD (n=103) and placebo (n=101) from CLARITY had lymphocytes and additional blood cells analyzed. CLARITY: CLAdRIbine Tablets treating multiple sclerosis orally; LLN: lower limit of normal.^{19,22}

MAVENCLAD AND SELECT B CELLS

Pooled clinical trial data: MAVENCLAD treatment resulted in sharper depletion, followed by recovery, of CD19+ B cells, compared to T cells^{2,15*++}



*Pooled data from CLARITY, CLARITY EXT, and PREMIERE.⁴

[†]Median CD19+ B cells reached a nadir at 2 months (median 0.018 \times 10[°] cells/µL) and then gradually increased.⁴ *MAVENCLAD/placebo were administered as 2 courses separated by 1 year (a maximum of 20 days of treatment). Each course consisted of 2 treatment weeks: 1 at the beginning of the first month and 1 at the beginning of the second month. Data from patients randomized to placebo in CLARITY or who received a cumulative dose of MAVENCLAD for 2 years in CLARITY or CLARITY EXT were included. Any relevant follow-up in CLARITY EXT and PREMIERE are also reported.^{3,4} CLARITY: CLAdRIbine Tablets treating multiple sclerosis orally; LLN: lower limit of normal.

MAVENCLAD AND SELECT CD4+ HELPER T CELLS, CD8+ CYTOTOXIC T CELLS^{4*}




CD8+ CYTOTOXIC T CELLS

In MS, contribute to CNS inflammation and damage^{5,16}

MAVENCLAD treatment resulted in⁴:

- Reduction in T cells
- Median CD8+ T-cell counts decreased, followed by recovery




CD4+ HELPER T CELLS

In MS, do not function correctly and are widely implicated as pro-inflammatory cells^{5,16}

MAVENCLAD treatment resulted in⁴:

- Reduction in T cells
- Median CD4+ T-cell counts decreased, followed by recovery









*Pooled data from CLARITY, CLARITY EXT, and PREMIERE. [†]MAVENCLAD/placebo were administered as 2 courses separated by 1 year (a maximum of 20 days of treatment). Each course consisted of 2 treatment weeks; 1 at the beginning of the first month and 1 at the beginning of the second month. Data from patients randomized to placebo in CLARITY or who received a cumulative dose of MAVENCLAD for 2 years in CLARITY or CLARITY EXT were included. Any relevant follow-up in CLARITY EXT and PREMIERE are also reported. CLARITY: CLAdRIbine Tablets treating multiple sclerosis orallY; CNS: central nervous system; LLN: lower limit of normal.4

SUMMARY OF MAVENCLAD ACTION ON SELECT IMMUNE CELLS IN CLINICAL STUDIES



SUMMARY OF MAVENCLAD ACTION ON SELECT IMMUNE CELLS IN CLINICAL STUDIES (CONT'D)



CONSIDER THE FOLLOWING ASPECTS AROUND LYMPHOCYTES **AND VACCINATIONS FOR PATIENTS**

MAVENCLAD can reduce the body's immune defense and may increase the likelihood of infection.^{3,22}

A complete blood count must be performed with a differential including lymphocyte count³

=

 Lymphocytes must be within normal limits before initiating the first treatment course and at least 800 cells/ μ L before initiating the second treatment course. If necessary, delay the second treatment course for up to 6 months to allow for recovery of lymphocytes to at least 800 cells/ μ L. If this recovery takes more than 6 months, the patient should not receive further treatment with MAVENCLAD

Immunizations: Administer all immunizations according to immunization guidelines prior to starting MAVENCLAD³

 Administer live-attenuated or live vaccines. at least 4 to 6 weeks prior to starting MAVENCLAD because of a risk of active vaccine infection. Vaccinate patients who are antibody-negative for varicella zoster virus, eq, with either an inactivated recombinant vaccine (2 doses) or a liveattenuated virus vaccine (single dose) prior to initiation with MAVENCLAD

Vaccinations: Vaccination can be considered until 4-6 weeks prior to starting each MAVENCLAD course only if white blood cell counts are within normal limits³

 Avoid vaccination with live-attenuated or live vaccines during and after MAVENCLAD treatment while the patient's white blood cell counts are not within normal limits

• Administer anti-herpes prophylaxis in patients with lymphocyte counts less than 200 cells per microliter



SUMMARY



Adaptive and innate immune cells play a major role in MS, with innate immune cells serving as immune surveillance and adaptive immune cells serving as key drivers of neuroinflammation.^{1,12}

MAVENCLAD has the greatest impact on the adaptive immune system; therefore, there is less disruption of the innate immune cells.^{19,21,22}

MAVENCLAD is thought to preferentially target B and T lymphocytes, and is associated with a **reduction and subsequent recovery in lymphocyte count.**^{4,18,19}



e cells serving as inflammation.^{1,12} **tem;** 2

AFTER COMPLETING THIS LEARNING SESSION, PLEASE TAKE A FEW MOMENTS TO CONSIDER THE FOLLOWING QUESTIONS

What are 3 of the most important "take-home" messages you have learned during this session?

V

Have your most important questions been answered? If you answered no, how can you learn more? V

Do you feel there are opportunities to use the information in this learning session to improve your consultations, education, and counseling of patients with RMS?

- If you answered no, why?
- If you answered yes, how will you do this?
- What challenges might you experience?
- How will you overcome these challenges?







1. B and T cells normally protect us against infections and other diseases. In certain conditions, such as MS, the immune system attacks healthy cells.¹



=

1. B and T cells normally protect us against infections and other diseases. In certain conditions, such as MS, the immune system attacks healthy cells.¹

True		
False		
		SEE SLIDES 9-13 TO REVIEW

2. Which of the following describes innate immune cells?¹⁴ Please indicate all that apply



2. Which of the following describes innate immune cells?¹⁴ Please indicate all that apply



NK cells, neutrophils, and/or monocytes

B cells and **T** cells

SEE SLIDE 15 TO REVIEW

3. Which of the following is a feature of immunodepletion followed by repopulation?^{3,17} Please indicate all that apply



3. Which of the following is a feature of immunodepletion followed by repopulation?^{3,17} Please indicate all that apply

Continuous administration

Therapy administered intermittently as a short course

Dosing followed by depletion and repopulation

Clinical efficacy extends beyond active dosing

Ongoing modulation of immune function during active treatment without immunodepletion

SEE SLIDES 18-20 TO REVIEW

4. MAVENCLAD has the greatest impact on the adaptive immune system; therefore, there is less disruption to the innate immune cells. This allows the innate cells to help fight against new infections.^{19,21}



4. MAVENCLAD has the greatest impact on the adaptive immune system; therefore, there is less disruption to the innate immune cells. This allows the innate cells to help fight against new infections.^{19,21}

True		
False		
		SEE SLIDE 24 TO REVIEW




ADDITIONAL RESOURCES



CONTINUING THE MAVENCLAD NURSE TOOLKIT

Be sure to review the full Nurse Toolkit, including modules on:





Practical considerations for managing patients with MS taking MAVENCLAD, coming in 2022



REFERENCES



REFERENCES

- 1. What is an immune-mediated disease? National Multiple Sclerosis Society. 2021. Accessed July 22, 2021. https://www.nationalmssociety.org/What-is-MS/Definition-of-MS/Immune-mediated-disease
- 2. Krumbholz M, Derfuss T, Hohlfeld R, Meinl E. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol. 2012;8(11):613-623.
- 3. MAVENCLAD [prescribing information]. Rockland, MA: EMD Serono, Inc; 2019.
- 4. Comi G, Cook S, Giovannoni G, et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:168-174.
- 5. Nally FK, De Santi C, McCoy CE. Nanomodulation of macrophages in multiple sclerosis. Cells. 2019;8(6):543.
- 6. Relapsing-remitting MS (RRMS). National Multiple Sclerosis Society. 2021. Accessed July 22, 2021. https://www.nationalmssociety.org/What-is-MS/Types-of-MS/Relapsing-remitting-MS
- 7. Giovannoni G. Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm. Curr Opin Neurol. 2018;31(3):233-243.
- 8. Changes in multiple sclerosis disease-course (or "type") descriptions. National Multiple Sclerosis Society. 2021. Accessed July 22, 2021. https://www.nationalmssociety.org/NationalMSSociety/media/MSNational/Charts-Graphics/new MSdiseasecourses table.pdf
- 9. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-286.
- 10. McKay KA, Kwan V, Duggan T, et al. Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review. Biomed Res Int. 2015;1-11.
- 11. Secondary progressive MS (SPMS). National Multiple Sclerosis Society. 2021. Accessed July 22, 2021. https://www.nationalmssociety.org/What-is-MS/Types-of-MS/Secondary-progressive-MS
- 12. Warrington R, Watson W, Kim HL, Antonetti FR. An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol. 2011;7:S1.
- 13. Gross CC, Shulte-Mecklenbeck A, Wiendl H, et al. Regulatory functions of natural killer cells in multiple sclerosis. Front Immunol. 2016:7:606.
- 14. Woodberry T, Bouffler SE, Wilson AS, Buckland RL, Brustle A. The emerging role of neutrophil granulocytes in multiple sclerosis. J Clin Med. 2018;7(12):511.

- Neurology. 2012;78(11):823-832.
- Ther Adv Neurol Disord. 2019;12:1-31.
- 2011:34(1):28-35.
- San Diego, CA.
- 20. CTCAE Version 5, November 17, 2017.
- Research in Multiple Sclerosis (ECTRIMS); September 9-12, 2009; Dusseldorf, Germany.
- via B-cell depletion. Neurol Neuroimmunol Neuroinflamm. 2017;4(4):e360.
- 23. Data on file. Merck KGaA, Darmstadt, Germany.
- 24. Benet LZ, Zia-Amirhosseini P. Basic principles of pharmacokinetics. Toxicol Pathol. 1995;23(2):115-123.
- the healthy adult population in Switzerland. Eur J Haematol. 2004;72(3):203-212.
- haematology-normal-adult-reference-ranges/

MAVENCLAD is a registered trademark of Merck KGaA, Darmstadt, Germany or its affiliates. ©2021 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada. EMD Serono, Inc., One Technology Place, Rockland, MA 02370 US-MAV-01086 08/21

This message is intended for healthcare professionals in the United States only.

15. Disanto G, Morahan JM, Barnett MH, Giovannoni G, Ramagopalan SV. The evidence for a role of B cells in multiple sclerosis.

16. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545-558.

17. Klotz L, Havla J, Schwab N, et al. Risks and risk management in modern multiple sclerosis immunotherapeutic treatment.

18. Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol.

19. Soelberg-Sorensen P, Dandond F, Hicking C, Giovannoni G. Innate immune cell counts in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY Extension. Poster presented at: Third Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018 [P061]; February 1-3, 2018;

21. Rieckmann P, Comi G, Cook S, et al. Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96-week, phase III, double-blind, placebo-controlled CLARITY study. Poster presented at: 25th Congress of the European Committee for Treatment and

22. Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K. Both cladribine and alemtuzumab may effect MS

25. Bisset LR, Lung TL, Kaelin M, Ludwig E, Dubs RW. Reference values for peripheral blood lymphocyte phenotypes applicable to

26. Haematology Normal Adult Reference Ranges. The Royal Wolverhampton NHS Trust. May 19, 2017. Accessed April 26, 2021. https://www.royalwolverhampton.nhs.uk/services/service-directory-a-z/pathology-services/departments/haematology/